[Alpha Tau in Alpha Tau] Alpha Tau announces FDA approval of IDE supplement to expand pilot trial of Alpha DaRT® to thirty patients with pancreatic cancer in two cohorts, with locally advanced or metastatic disease

JERUSALEM, Feb. 03, 2025 (GLOBE NEWSWIRE) — Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT^®, announced today an approval from the U.S. Food and Drug Administration (FDA) of an Investigational Device Exemption (IDE) supplement to the IDE previously announced on Jan 27, 2025, which had approved a clinical study examining the combination of Alpha DaRT and first-line chemotherapy in 12 patients with newly diagnosed metastatic pancreatic cancer, allowing expansion of the clinical trial to a broader group of pancreatic cancer patients.

Read more here.